US 12,102,617 B2
Antimicrobial compositions containing a synergistic combination of activated creatinine and an imidazole antifungal agent
Thomas McDonald, Omaha, NE (US); and Steven M. Tracy, Davis, CA (US)
Assigned to Board of Regents of the University of Nebraska, Lincoln, NE (US)
Filed by Board of Regents of the University of Nebraska, Lincoln, NE (US)
Filed on Jun. 6, 2022, as Appl. No. 17/832,838.
Application 17/832,838 is a continuation of application No. 16/474,173, granted, now 11,351,153, previously published as PCT/US2017/068505, filed on Dec. 27, 2017.
Claims priority of provisional application 62/439,450, filed on Dec. 27, 2016.
Prior Publication US 2022/0387390 A1, Dec. 8, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4166 (2006.01); A61K 9/00 (2006.01); A61K 31/4164 (2006.01); A61P 31/04 (2006.01); A61P 31/10 (2006.01)
CPC A61K 31/4166 (2013.01) [A61K 9/0014 (2013.01); A61K 31/4164 (2013.01); A61P 31/04 (2018.01); A61P 31/10 (2018.01)] 11 Claims
 
1. A method for increasing at least one of the antibacterial efficacy of activated creatinine or the antifungal efficacy of an antifungal agent, wherein the method comprises providing a composition consisting of activated creatinine and an imidazole antifungal agent selected from the group consisting of clotrimazole, ketoconazole, miconazole, and combinations thereof, wherein the imidazole antifungal agent is present in the composition in an amount of about 0.5 mol % to about 15 mol % of the combination of the imidazole antifungal agent and the activated creatinine, such that the antibacterial efficacy of the composition is greater than the antibacterial efficacy of activated creatinine alone, the antifungal efficacy of the composition is greater than the antifungal efficacy of the imidazole antifungal agent alone, or both.